{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:25:12Z","timestamp":1761895512538},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T00:00:00Z","timestamp":1341273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s12185-012-1125-7","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T16:57:08Z","timestamp":1341248228000},"page":"254-262","source":"Crossref","is-referenced-by-count":17,"title":["Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients \u226565\u00a0years old with relapsed or refractory multiple myeloma"],"prefix":"10.1007","volume":"96","author":[{"given":"Asher A.","family":"Chanan-Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene S.","family":"Swern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,3]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/10428190500085024","volume":"46","author":"L Mileshkin","year":"2005","unstructured":"Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma. 2005;46:951\u201366.","journal-title":"Leuk Lymphoma"},{"key":"1125_CR2","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results (SEER). Fast Stats. http:\/\/seer.cancer.gov\/faststats (accessed 18 July 2011)."},{"key":"1125_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21\u201333.","journal-title":"Mayo Clin Proc"},{"key":"1125_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2001.00301.x","volume":"66","author":"P Rodon","year":"2001","unstructured":"Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol. 2001;66:11\u20137.","journal-title":"Eur J Haematol"},{"key":"1125_CR5","unstructured":"Palumbo A, Avonto I, Bringhen S, Falcone A, Liberati M, Boccadoro M. Hematologic cancer in the elderly: new and existing therapeutic strategies. http:\/\/www.asco.org\/ASCOv2\/Home\/Education%20&%20Training\/Educational%20Book\/PDF%20Files\/2007\/07geriatric02.pdf (accessed 18 July 2011)."},{"key":"1125_CR6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/10428190601059852","volume":"48","author":"F Cavallo","year":"2007","unstructured":"Cavallo F, Ambrosini MT, Rus C, Boccadoro M, Palumbo A. The treatment of the elderly multiple myeloma patients. Leuk Lymphoma. 2007;48:469\u201380.","journal-title":"Leuk Lymphoma"},{"key":"1125_CR7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3816\/CLM.2006.n.004","volume":"6","author":"R Suppiah","year":"2006","unstructured":"Suppiah R, Srkalovic JG, Hussein MA. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. Clin Lymphoma Myeloma. 2006;6:301\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"key":"1125_CR8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123\u201332.","journal-title":"N Engl J Med"},{"key":"1125_CR9","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133\u201342.","journal-title":"N Engl J Med"},{"key":"1125_CR10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147\u201352.","journal-title":"Leukemia"},{"key":"1125_CR11","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1125_CR12","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Common Toxicity Criteria (CTC) v2.0, published April 30, 1999. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_20 (accessed 18 July 2011)."},{"key":"1125_CR13","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","volume":"112","author":"M Wang","year":"2008","unstructured":"Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112:4445\u201351.","journal-title":"Blood"},{"key":"1125_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","volume":"137","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429\u201335.","journal-title":"Br J Haematol"},{"key":"1125_CR15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1600-0609.2010.01469.x","volume":"85","author":"F Gay","year":"2010","unstructured":"Gay F, Rajkumar SV, Falco P, Kumar S, Dispenzieri A, Petrucci MT, et al. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol. 2010;85:200\u20138.","journal-title":"Eur J Haematol"},{"key":"1125_CR16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211\u201325.","journal-title":"Clin Infect Dis"},{"key":"1125_CR17","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/leu.2011.126","volume":"25","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia. 2011;25:1620\u20136.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1125-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1125-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:01:47Z","timestamp":1559451707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1125-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1125-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,3]]}}}